New Appointments at TB Alliance
WHO's tuberculosis program leader and the CFO of Ultragenyx jojn Board of Directors.
Mario Raviglione, MD, director of the Global TB Programme at the World Health Organization (WHO), and Shalini Sharp, the chief financial officer of Ultragenyx Pharmaceutical Inc., have been appointed to the Board of Directors of TB Alliance (New York, NY), an international not-for-profit organization with the mission of developing improved tuberculosis (TB) treatments. Dr. Raviglione began working for WHO in 1991 and became director of the Global TB Programme in 2003. He serves on a variety of scientific committees, has published extensively on the TB epidemic, and has won numerous awards for his work on TB control. Ms. Sharp has been the chief financial officer and senior vice president, finance, of Ultragenyx, a clinical-stage biotechnology company developing medicines to treat rare diseases, since 2012.
Is Artificial Intelligence a ‘Product’? Products Liability Implications for AI-Based Products
April 10th 2025As the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not always fit to provide remedies for harm that can result from using novel product types.
